Related Experiment Video
Updated: Aug 9, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Can treatment with somatostatin analogs replace neurosurgery?
M Lorenzo-Solar1, A Castro, R Peino
1Endocrine Division, Department of Medicine, Complejo Hospitalario Universitario Santiago, Spain.
Journal of Endocrinological Investigation
|April 22, 2006
Summary
The best initial treatment for acromegaly remains debated. While surgery offers a cure, somatostatin analogs provide effective tumor control and pituitary function preservation.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Acromegaly treatment strategies are evolving.
- Transsphenoidal surgery is the traditional first-line therapy.
- Newer medical treatments, like somatostatin analogs, are emerging.
Purpose of the Study:
- To compare the advantages and disadvantages of transsphenoidal surgery versus somatostatin analogs as first-line treatment for acromegaly.
- To inform clinical decision-making in acromegaly management.
Main Methods:
- This manuscript provides a discussion and comparative analysis of existing treatment options.
- Literature review and clinical expertise synthesis.
Main Results:
- Transsphenoidal surgery offers potential cure and cost-effectiveness but carries surgical risks.
- Somatostatin analogs are effective in controlling tumor growth, shrinking tumors, and preserving pituitary function, with convenient administration.
- Both treatments have distinct benefits and drawbacks influencing patient outcomes.
Conclusions:
- The choice between surgery and somatostatin analogs for acromegaly depends on individual patient factors and treatment goals.
- Further research may clarify optimal sequencing and combination therapies.
